Does Quartz Health Solutions Cover Metformin?

What Is Metformin and Why Does Coverage Matter?

Metformin hydrochloride is the most commonly prescribed oral glucose-lowering medication in the United States, with more than 90 million prescriptions dispensed annually. The FDA first approved the immediate-release formulation under the brand name Glucophage in 1994, and generics entered the market in 2002, collapsing prices dramatically. Despite costing pennies per tablet at retail, insurance tier placement still determines whether patients pay nothing, a standard generic copay, or full cash price, which matters most when a plan imposes deductibles or when a prescriber orders the extended-release formulation that may carry a slightly higher tier assignment. The American Diabetes Association 2024 Standards of Care designate metformin as the preferred initial pharmacologic agent for most adults with Type 2 diabetes, specifically when diet and exercise alone are insufficient.

The drug's mechanism centers on reducing hepatic glucose output by inhibiting mitochondrial complex I, which lowers fasting plasma glucose without causing direct insulin secretion or hypoglycemia at standard doses. A 2002 landmark analysis of the UK Prospective Diabetes Study (UKPDS 34, N=1,704 overweight patients) showed metformin reduced all-cause mortality by 36% versus conventional dietary therapy over a 10-year median follow-up (PMID 9742976). That mortality signal, unusual for a glucose-lowering drug, is one reason clinicians continue to prefer it even as newer agents like GLP-1 receptor agonists gain market share.

Beyond diabetes, metformin is under active investigation for longevity applications. The TAME (Targeting Aging with Metformin) trial, a six-year, multi-site, placebo-controlled study registered at ClinicalTrials.gov (NCT03309007), is examining whether 1 to 500 mg/day of metformin delays the onset of age-related chronic diseases in adults aged 65 to 79 without diabetes. Off-label longevity use is not yet FDA-approved, which affects how insurers, including Quartz, handle prior authorization for non-diabetic indications (NIH NIA TAME information).

How Quartz Health Solutions Structures Its Drug Formulary

Quartz Health Solutions is a Wisconsin-based nonprofit insurer offering commercial individual and family plans, employer group coverage, and Medicare Advantage products across Wisconsin and parts of Iowa. Its formulary uses a tiered co-insurance model that most members encounter as a five-tier structure, though specific tier counts differ by plan document.

Tier 1 covers preferred generics, typically with a $0 to $10 copay per 30-day supply. Tier 2 covers non-preferred generics or preferred brand drugs, usually at $25 to $45. Tier 3 covers non-preferred brands, and Tiers 4 to 5 cover specialty medications, which carry the highest cost-sharing. Metformin HCl immediate-release tablets (500 mg, 850 mg, 1 to 000 mg) almost universally sit at Tier 1 across Quartz commercial plans because the drug meets every criterion for preferred generic status: it has multiple FDA-approved manufacturers, a decades-long safety record, and a cost-effectiveness profile endorsed by the ADA (ADA Pharmacologic Approaches 2024).

Metformin extended-release tablets may land at Tier 1 or Tier 2 depending on the specific plan year and manufacturer on the formulary at the time of dispensing. Members should verify their specific plan's Summary of Benefits and Coverage (SBC) document, available through the Quartz member portal, before assuming ER formulations share the same tier as immediate-release.

Does Quartz Require Prior Authorization for Metformin?

For standard Type 2 diabetes use, Quartz does not generally require prior authorization for metformin. The drug is a first-line agent per every major guideline, and payers that apply PA requirements to first-line generics routinely face medical policy challenges and member complaints. The ADA's 2024 Standards of Care explicitly state: "Metformin remains a cost-effective, safe, and well-tolerated medication and should be continued as long as it is tolerated and not contraindicated" (PMID 38078584).

Off-label prescribing is a different matter. A prescriber ordering metformin for a non-diabetic patient, such as someone with polycystic ovary syndrome (PCOS), prediabetes, or a longevity protocol, may trigger a prior authorization request depending on the diagnosis code submitted with the prescription. PCOS is perhaps the most common off-label use; the American College of Obstetricians and Gynecologists (ACOG) supports metformin use in PCOS for menstrual irregularity and ovulation induction (ACOG Practice Bulletin 194). Members in that situation should ensure their prescriber includes the PCOS ICD-10 code (E28.2) on the prescription, which often resolves authorization questions without a formal PA submission.

For prediabetes (ICD-10 R73.09), the evidence is also strong. The Diabetes Prevention Program (DPP, N=3,234) showed metformin 850 mg twice daily reduced progression from prediabetes to diabetes by 31% over 2.8 years, compared to placebo, though lifestyle intervention reduced it by 58% (PMID 11832527). Some Quartz plans may require documentation of prediabetes lab values (HbA1c 5.7 to 6.4% or fasting glucose 100 to 125 mg/dL) before approving metformin for that indication.

What Does Metformin Actually Cost With Quartz Coverage?

With Tier 1 placement and no deductible applied, most Quartz commercial members pay $0 to $10 per 30-day supply of metformin IR. On high-deductible health plans (HDHPs), the member pays the negotiated rate until the deductible is met. The average negotiated price for metformin IR 500 mg (60 tablets, 30-day supply) through large commercial insurers runs approximately $4 to $12 at major retail pharmacies, according to CMS drug pricing data (CMS Drug Spending Dashboard).

Extended-release formulations cost slightly more, typically $8 to $25 negotiated, and may carry a higher copay if the plan places them at Tier 2. Metformin ER 500 mg (60 tablets) at GoodRx cash price runs approximately $9 to $18 without insurance at national chains, which means that even uninsured members or those in HDHP deductible phases rarely face a meaningful financial barrier.

Medicare Advantage members enrolled in Quartz plans that include Part D coverage should check the plan's Annual Notice of Change (ANOC) each fall, because formulary tier assignments can shift between plan years. For the 2024 plan year, CMS data show metformin IR remains on the formulary of essentially all Medicare Part D plans at the lowest tier, with a $0 copay under the standard benefit design after the Inflation Reduction Act's drug pricing provisions took effect (CMS Medicare Part D Drug Spending 2024).

Metformin Dosing, Formulations, and What Quartz Will Typically Dispense

The FDA-approved dosing range for Type 2 diabetes in adults is 500 mg to 2 to 550 mg per day, administered in divided doses with meals to reduce gastrointestinal side effects. Most clinicians start at 500 mg once or twice daily with food and titrate upward by 500 mg per week as tolerated, targeting 1 to 500 mg to 2 to 000 mg per day for full glycemic effect (FDA Prescribing Information, Metformin HCl).

Common formulations covered under typical Quartz formularies:

• Metformin HCl IR 500 mg tablets
• Metformin HCl IR 850 mg tablets
• Metformin HCl IR 1 to 000 mg tablets
• Metformin HCl ER 500 mg tablets
• Metformin HCl ER 750 mg tablets
• Metformin HCl ER 1 to 000 mg tablets

Liquid metformin (500 mg/5 mL oral solution, brand name Riomet ER) is rarely covered at Tier 1 because it is a branded product. Prescribers ordering liquid metformin for patients with swallowing difficulties should anticipate Tier 3 placement or a PA requirement.

The FDA added a black-box warning for lactic acidosis in 2016 when eGFR guidance was updated. Metformin is contraindicated when eGFR falls below 30 mL/min/1.73 m² and requires dose reduction consideration when eGFR is 30 to 45 mL/min/1.73 m². Quartz's pharmacy benefit manager will flag renal function through claims history in some cases, but the prescriber is primarily responsible for ordering baseline renal labs (FDA Safety Communication, Metformin Renal).

Metformin vs. Newer Diabetes Drugs: Why Coverage Tier Matters

GLP-1 receptor agonists such as semaglutide (Ozempic, Wegovy) and SGLT-2 inhibitors such as empagliflozin (Jardiance) have demonstrated cardiovascular and renal benefits that metformin has not replicated in dedicated outcomes trials. The EMPA-REG OUTCOME trial (N=7,020) showed empagliflozin reduced cardiovascular death by 38% versus placebo in high-risk Type 2 diabetes patients (PMID 26378978). SUSTAIN-6 (N=3,297) showed semaglutide 0.5 mg and 1.0 mg reduced the composite of cardiovascular death, non-fatal MI, and non-fatal stroke by 26% versus placebo (PMID 27633186).

Those drugs, however, land at Tier 4 or 5 on most Quartz formularies, with monthly costs after copay running $50 to $150 or more, and often require step therapy through metformin first. That step-therapy requirement means Quartz may require documented metformin use or intolerance before approving GLP-1 agonists or SGLT-2 inhibitors at preferred cost-sharing, even in patients with established cardiovascular disease who might benefit most from the newer agents.

The ADA 2024 Standards state: "In patients with Type 2 diabetes and established cardiovascular disease, heart failure, or chronic kidney disease, specific GLP-1 receptor agonists or SGLT-2 inhibitors with proven benefit should be recommended independent of baseline HbA1c" (PMID 38078584). Patients in those high-risk categories should work with their prescriber to submit clinical documentation that overrides the step-therapy requirement when medically necessary.

The Longevity Use Case: Metformin for Non-Diabetic Adults

Interest in metformin as a longevity compound has grown sharply since the 2014 publication of epidemiologic data suggesting that diabetic patients on metformin outlived age-matched non-diabetic controls not on the drug. The observational study by Bannister et al. (N=78,241 metformin users vs. 12,222 sulfonylurea users vs. 90,463 matched non-diabetic controls) showed metformin users had a 15% lower all-cause mortality hazard than non-diabetic controls (PMID 24861925). That finding, while hypothesis-generating, drove clinician interest in prescribing metformin off-label to non-diabetic adults focused on healthspan.

Quartz's coverage for this use case is not guaranteed. The insurer follows standard utilization management practices, meaning a claim submitted with ICD-10 code Z51.89 (encounter for other specified aftercare) or a longevity-focused code will likely be flagged. Prescribers who want Quartz to cover metformin for a non-diabetic patient should anchor the diagnosis to the most clinically defensible approved indication, whether prediabetes, insulin resistance, or PCOS, rather than relying on a longevity-framing that has no current FDA-approved status.

The HealthRX clinical team uses the following framework when evaluating insurance coverage for metformin in non-diabetic patients on longevity protocols:

1. Document fasting glucose and HbA1c at baseline. If HbA1c is 5.7% or above, prediabetes coding is defensible and commonly covered.
2. Document insulin resistance via HOMA-IR or fasting insulin if glucose is normal, which may support metabolic syndrome coding (E88.81).
3. Confirm eGFR above 45 mL/min/1.73 m² before prescribing.
4. Submit the prescription with the most specific applicable ICD-10 code. Generic "wellness" codes rarely survive PA review.
5. If denied, request a peer-to-peer review citing UKPDS mortality data and the DPP's 31% diabetes prevention efficacy.

What to Do If Quartz Denies Metformin Coverage

Denials are uncommon for standard diabetes use but do occur for off-label indications. The appeals process at Quartz follows Wisconsin insurance law and the federal internal appeals timeline: a standard internal appeal decision is required within 60 days of the request, and urgent appeals within 72 hours. First-level appeals should include the prescriber's clinical notes, relevant lab values, and at least one peer-reviewed citation supporting the prescribed indication (CMS External Appeals Information).

If the internal appeal fails, Wisconsin members have access to external independent review through the Office of the Commissioner of Insurance (OCI). Federal external review rights under the ACA apply to non-grandfathered plans. An independent reviewer overturned insurer denials for metformin in PCOS cases at a rate of approximately 60 to 70% in state-level data where such statistics are published, though Quartz-specific denial and overturn rates are not publicly reported.

While the appeal is pending, consider these short-term options. GoodRx coupons reduce metformin IR to $4 to $9 at major chains. Mark Cuban's Cost Plus Drugs (costplusdrugs.com) lists metformin 500 mg (180 tablets) at approximately $5. Generic metformin ER is similarly inexpensive. The financial burden of an appeal delay is low for this specific drug, which is one reason patients and prescribers often choose to pay cash during the appeal rather than wait.

Monitoring Requirements Quartz May Tie to Continued Coverage

Some Quartz employer group plans impose medication therapy management (MTM) program participation for members on chronic medications, including metformin. MTM programs are required for Medicare Part D beneficiaries meeting specific criteria under CMS guidelines. Participation typically involves an annual comprehensive medication review (CMR) with a pharmacist.

For standard diabetes management, the ADA recommends monitoring HbA1c every three months until stable, then every six months, as well as annual eGFR and urinary albumin-to-creatinine ratio (UACR) checks. Vitamin B12 levels deserve monitoring every one to two years with long-term metformin use, because the drug reduces B12 absorption in approximately 10 to 30% of users over time; the mechanism involves competitive inhibition of calcium-dependent ileal membrane transport (PMID 20488910). Some Quartz plans will cover annual B12 lab draws specifically coded to metformin-related deficiency monitoring.

Quartz Medicare Advantage and Metformin: Specific Considerations

Medicare Advantage members covered under Quartz receive drug benefits through an embedded Part D plan. The Inflation Reduction Act of 2022 capped out-of-pocket drug costs at $2,000 per year starting in 2025 and required $0 cost-sharing for covered insulin products. Metformin, while not insulin, was already at or near $0 cost-sharing for most Medicare Part D beneficiaries before the IRA took effect, because of its deeply generic price point. CMS data confirm that median total Part D spending per beneficiary for metformin was $24 annually in 2022, inclusive of plan and beneficiary shares (CMS Part D Drug Spending Data).

Medicare Advantage members with End Stage Renal Disease (ESRD) or advanced CKD should note that metformin is contraindicated at eGFR below 30, and Quartz's Part D plan may generate a drug utilization review (DUR) alert if claims data suggest severe renal impairment. The prescribing physician's obligation to monitor renal function annually, or more frequently in CKD patients, remains regardless of the insurer's DUR processes.